Management with know-how within vaccine development

The company management has the wide competence that has made possible Intervacc’s development of a vaccine that protects horses against strangles. Intervacc has a comprehensive research competence in microbiology, infection biology, gene technology, and also access to new test methods for vaccine development.
The board members of Intervacc are:
Rune Bergman, DVM, PhD, Chairman and CEO of Nordvacc Läkemedel.
Kenneth Janzon, Technical director of Intervacc AB and Nordvacc AB.
Anders Franklin, DVM, PhD, and CEO of Intervacc AB.
Bengt Guss, Professor at the Swedish University of Agricultural Sciences (SLU).
Jan-Ingmar Flock, Professor at the Karolinska Institutet.
Stefan Ståhl, Professor in Molecular Biotechnology at the Royal Institute of Technology (KTH) and was appointed as Dean for the School of Biotechnology in 2005.